VAP检测血浆脂蛋白亚组分的新进展及应用分析  

Research progress of VAP in determining plasma lipoprotein subfractions

作　　者：梁纯子 朱满[1] 涂建成[1] LIANG Chunzi;ZHU Man;TU Jiancheng(Department of Clinical Laboratory,Faculty of Laboratory Medicine,Center for Gene Diagnosis,Zhongnan Hospital of Wuhan University,Wuhan 430000,Hubei,China)

机构地区：[1]武汉大学中南医院检验科检验系基因诊断中心,湖北武汉430000

出　　处：《检验医学》2019年第1期76-81,共6页Laboratory Medicine

基　　金：武汉大学自主科研项目(413000061);武汉大学中南医院科技创新培育基金(znpy2016046)

摘　　要：越来越多的证据强调特殊的血浆脂蛋白亚组分,如脂蛋白残粒(RLP)、脂蛋白(a)[Lp(a)]、高密度脂蛋白(HDL)亚型(HDL2、HDL3)以及颗粒浓度,如小而密低密度脂蛋白颗粒(sd-LDL-P)等在心血管疾病(CVD)进展中的关键作用。这些指标型别和数量上的改变与CVD风险和治疗选择密切相关。垂直梯度离心(VAP)参考经典的超速离心血脂检测原理,能较为完整地分离血浆脂蛋白颗粒,并对其内部的胆固醇水平、体积、密度和型别进行综合分析,为相关疾病的早期筛查、风险评价和治疗选择提供较为全面的血脂检测数据,弥补了传统血脂项目的空白。过去20年,北美地区在VAP的应用中积累了大量的科研及临床资料。文章简要介绍了VAP在血浆脂蛋白亚组分和颗粒检测方法学上的特点及其在CVD风险评估中的应用新进展。More evidence is accentuating the special subfractions of plasma lipoproteins,including remnant-like lipoprotein particles(RLP),lipoproteins(a)[Lp(a)],high-density lipoprotein(HDL)subfractions(HDL2 and HDL 3)and particle concentration,like small density low-density lipoprotein particle(sd-LDL-P),in the progression of cardiovascular disease(CVD).The changes of pattern and number of these indicators are closely related to CVD risk and treatment strategy.Vertical auto profile(VAP)refers to the classical principle of ultracentrifuge lipid determination,which can effectively realize complete separation of plasma lipoprotein particles.After the comprehensive analysis of lipoprotein internal cholesterol level,volume,density and particle pattern,VAP provides comprehensive blood lipid data for the early screening and risk evaluation of related diseases,making up for the gaps in traditional blood lipid programs.VAP has accumulated a large amount of scientific researches and clinical data in North America over the past 20 years.This review briefly introduces its characteristics in plasma lipoprotein subfractions and particle determination and presents new progress of its application in CVD risk management.

关 键 词：垂直梯度离心 脂蛋白 脂蛋白亚组分 心血管疾病 风险评估 

分 类 号：R446.1[医药卫生—诊断学]